Raloxifene increased bone mineral density in the spine and hips of postmenopausal women using long-term glucocorticoids

Robbins, John
September 2011
ACP Journal Club;9/20/2011, Vol. 155 Issue 3, p3
Academic Journal
Case Study
A case study on 114 adults women, who were postmenopausal for more than or equal to 12 months is conducted to compare the impact of raloxifene and placebo in preventing bone mineral density (BMD) loss in them. Randomized placebo-controlled trial (RCT) were conducted and exclusion criteria involved hypercoagulability risk factors. It is found that Raloxifene increased lumbar spine and total hip bone mineral density.


Related Articles

  • 2011 - Raloxifene increased bone mineral density in the spine and hips of postmenopausal women using long-term glucocorticoids. Robbins, John // ACP Journal Club;9/20/2011, Vol. 155 Issue 3, p3 

    Question Is raloxifene better than placebo for preventing bone mineral density (BMD) loss in postmenopausal women using long-term glucocorticoids? Methods Design Randomized placebo-controlled trial (RCT). ClinicalTrials.gov NCT00371956. Allocation Unclear allocation concealment.* Blinding...

  • Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women. Delmas, Pierre D.; Bjarnason, Nina H.; Mitlak, Bruce H.; Ravoux, Anne-Catherine; Shah, Aarti S.; Huster, William J.; Draper, Michael; Christiansen, Claus // New England Journal of Medicine;12/04/97, Vol. 337 Issue 23, p1641 

    Background: Long-term estrogen therapy can reduce the risk of osteoporotic fracture and cardiovascular disease in postmenopausal women. At present, however, these beneficial effects are not separable from undesirable stimulation of breast and endometrial tissues. Methods: We studied the effect...

  • Investigational drug increased BMD in postmenopausal women with low bone density. Haigh, Christen; Kalvaitis, Katie // Endocrine Today;10/25/2008, Vol. 6 Issue 19, p8 

    The article reports on a study which revealed the safety and effectiveness of odanacatib in increasing lumbar spine and total hip bone mineral density in postmenopausal women.

  • Raloxifene: A Review of its Use in Postmenopausal Osteoporosis. Clemett, D.; Spencer, C.M. // Drugs;Aug2000, Vol. 60 Issue 2, p379 

    Raloxifene is a selective estrogen receptor modulator that partially mimics the effects of estrogens in bone and the cardiovascular system, while functioning as an antiestrogen in endometrial and breast tissue. In randomised placebo-controlled studies involving postmenopausal women or patients...

  • Recommendations for raloxifene use in daily clinical practice in the Swiss setting. Lippuner, Kurt; Buchard, P.; Geyter, C.; Imthurn, B.; Lamy, O.; Litschgi, M.; Luzuy, F.; Schiessl, K.; Stute, P.; Birkhäuser, M. // European Spine Journal;Dec2012, Vol. 21 Issue 12, p2407 

    Background/aim: Raloxifene is the first selective estrogen receptor modulator that has been approved for the treatment and prevention of osteoporosis in postmenopausal women in Europe and in the US. Although raloxifene reduces the risk of invasive breast cancer in postmenopausal women with...

  • Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Delmas, P. D.; Davis, S. R.; Hensen, J.; Adami, S.; van Os, S.; Nijland, E. A. // Osteoporosis International;Aug2008, Vol. 19 Issue 8, p1153 

    A randomized trial was conducted in osteopenic postmenopausal women to compare the efficacy of tibolone versus raloxifene on BMD of the lumbar spine and hip. Tibolone increased lumbar spine and total hip BMD to a statistically significantly greater extent than raloxifene after two years of...

  • Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Robert S. Weinstein; A. Michael Parfitt; Robert Marcus; Maria Greenwald; Gerald Crans; Douglas B. Muchmore // Osteoporosis International;Oct2003, Vol. 14 Issue 10, p814 

    Raloxifene, a nonsteroidal selective estrogen receptor modulator (SERM), increases bone mineral density (BMD), decreases biochemical markers of bone turnover, and prevents incident vertebral fractures in postmenopausal women, while sparing the breast and endometrium from the undesirable...

  • Hormone Therapy: The End of an Era.  // Annals of Internal Medicine;4/6/2004, Vol. 140 Issue 7, p540 

    Studies the bone loss by discontinuation of hormone therapy in postmenopausal women. Investigation of the effect on bone mineral density (BMD) after discontinuation of hormone therapy; Lack of an increase in BMD at the hip or in the lumbar spine due to the use of conjugated equine estrogen when...

  • COMMENTARY: Etidronate, calcium, or both did not reduce fracture rates in patients with asthma receiving glucocorticoid treatment. Jamal, Sophie A. // ACP Journal Club;Mar/Apr2005, Vol. 142 Issue 2, p44 

    The article comments on a study which examines the effects of etidronate, calcium, or placebo on bone mineral density (BMD) and fractures in patients taking oral or inhaled glucocorticoids or both for asthma. Patients randomized to etidronate had a 5% increase in lumbar spine BMD. No difference...


Read the Article


Sign out of this library

Other Topics